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Summary Statement 
The mode of action of lonidamine, an established anti-tumour drug, remains 
controversial. We show that lonidamine potently inhibits the mitochondrial pyruvate 
carrier and plasma membrane monocarboxylate transporters, accounting for many of its 
known effects on tumour cell metabolism and bioenergetics.  
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ABSTRACT 
Lonidamine (LND) is an anti-tumour drug particularly effective at selectively sensitising 
tumours to chemotherapy, hyperthermia and radiotherapy, although its precise mode of 
action remains unclear. It has been reported to perturb the bioenergetics of cells by 
inhibiting glycolysis and mitochondrial respiration, while indirect evidence suggests it 
may also inhibit L-lactic acid efflux from cells mediated by members of the proton-linked 
monocarboxylate transporter (MCT) family and also pyruvate uptake into the 
mitochondria by the mitochondrial pyruvate carrier (MPC). Here we test these 
possibilities directly. We demonstrate that LND potently inhibits MPC activity in isolated 
rat liver mitochondria (Ki 2.5 µM) and cooperatively inhibits L-lactate transport by MCT1, 
MCT2 and MCT4 expressed in Xenopus laevis oocytes with K0.5  and Hill Coefficient 
values of 36-40 µM and 1.65-1.85.  In rat heart mitochondria LND inhibited the MPC with 
similar potency and uncoupled oxidation of pyruvate was inhibited more effectively (IC50 
~7 µM) than other substrates including glutamate (IC50 ~20 µM). In isolated DB-1 
melanoma cells 1-10 µM LND increased L-lactate output, consistent with MPC inhibition, 
but higher concentrations (150 µM) decreased L-lactate output while increasing 
intracellular [L-lactate] > five-fold, consistent with MCT inhibition. We conclude that MPC 
inhibition is the most sensitive anti-tumour target for LND, with additional inhibitory 
effects on MCT-mediated L-lactic acid efflux and glutamine/glutamate oxidation. 
Together these actions can account for published data on the selective tumour effects of 
LND on L-lactate, intracellular pH (pHi) and ATP levels that can be partially mimicked by 
the established MPC and MCT inhibitor α-cyano-4-hydroxycinnamate.  
 
Abbreviations used 
AR-C155858, 6-[(3,5-Dimethyl-1H-pyrazol-4-yl)methyl]-5-[[(4S)-4-hydroxy-2-
isoxazolidinyl]carbonyl]-3-methyl-1-(2-methylpropyl)thieno[2,3-d]pyrimidine-2,4(1H,3H)-
dione; CHC, α-cyano-4-hydroxycinnamate; IC50, Inhibitor concentration giving 50% 
inhibition; ISB, Isolation buffer; LND, Lonidamine; MCT, Monocarboxylate Transporter; 
MPC, Mitochondrial Pyruvate Carrier; PCA, Perchloric acid; pHi, Intracellular pH; DIPEA, 
ethyldiisopropylamine.  
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INTRODUCTION 
Lonidamine (LND), first introduced in 1979 as an antispermadocidic agent [1], has 
limited antineoplastic activity as a single agent [2;3], but has exceptional potential in 
modulating the activities of conventional chemotherapeutic agents such as N-mustards 
[4;5], anthracyclines [4;6] and temozolomide [7], as well as hyperthermia [8;9], radiation 
therapy [10;11] and photodynamic therapy [12]. LND also exhibits a low level of toxicity 
to normal tissues when administered intravenously at concentrations below 400 mg/m2 
[13]. The detailed mechanism of LND action remains controversial. The initial claim that 
LND inhibited glycolysis at the level of mitochondrial hexokinase 2 [14] was based on 
decreases in extracellular L-lactic acid. However, it was subsequently shown that LND 
increased intracellular L-lactate and lowered the intracellular pH (pHi) and nucleoside 
triphosphate levels of human melanoma xenografts. It was proposed that these effects 
reflected inhibition of the transport of L-lactic acid across the plasma membrane 
mediated by the proton-linked monocarboxylate transporter (MCT) [15-17], but no direct 
evidence for this was provided. Nor was consideration given to which of the four MCT 
isoforms known to transport L-lactate [18] might be inhibited. Another MCT inhibitor, α-
cyano-4’-hydroxycinnamate (CHC), has been shown to exert similar effects to LND [19], 
but CHC is known to be substantially more potent an inhibitor of the mitochondrial 
pyruvate carrier (MPC) [18;20]. This led Nath et al. [5;21] to suggest that LND might also 
inhibit the MPC, although once again no direct evidence was presented. There is also 
evidence that LND inhibits mitochondrial respiration with different affinities for different 
substrates, but the exact sites of inhibition remains to be determined [22]. 
In this paper, we directly determine the effects of LND on MPC and MCT activity 
and show that the drug inhibits both processes with K0.5 values of 2.5 and 36-40 µM, 
respectively. We also investigate the effects of LND on uncoupled respiration of heart 
and liver mitochondria. In agreement with Floridi and Lehninger [22], we demonstrate 
that pyruvate oxidation is substantially more sensitive to inhibition by LND (IC50 ~7.5 µM) 
than that of glutamate plus malate (IC50 ~25 µM) or succinate (IC50 ~150 µM). We further 
demonstrate that in isolated DB-1 melanoma cells 1-10 µM LND increased L-lactate 
output, consistent with MPC inhibition, but at higher concentrations (150 µM) L-lactate 
output decreased while intracellular [L-lactate] increased > five-fold, consistent with MCT 
inhibition. Taken together, our data suggest that the combined inhibition of the MPC and 
MCTs by LND prevents both efflux of glycolytically derived L-lactic acid from the cell and 
its oxidation by mitochondria. The resulting decrease in intracellular pH inhibits 
glycolysis and, with the cell unable to compensate by oxidizing L-lactate / pyruvate, the 
cell experiences a bioenergetics crisis which is made worse by the effects of LND on the 
oxidation of other substrates such as glutamine. The combination of these effects can 
account for the increase in L-lactic acid and decrease in ATP levels as well as 
intracellular acidification that have been noted previously [4;5;15-17;21]. 
 
EXPERIMENTAL  
Materials 
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Radiochemicals were purchased from PerkinElmer Life Sciences (Beaconsfield, 
Bucks.,U.K.) while all other chemicals and biochemicals were obtained from Sigma-
Aldrich or Merck via VWR international Ltd (Poole, Dorset., U.K.). 
 
Methods 
Preparation of rat heart and liver mitochondria 
Hearts and livers were taken from male Wister rats (~275 g) and mitochondria prepared 
as described previously [23] by Dounce-Potter homogenisation at 4°C in isolation buffer 
(ISB: 300 mM sucrose, 2 mM EGTA and 10 mM Tris/HCl, pH 7.1) supplemented with 5 
mg / mL fatty acid free bovine serum albumin) followed by differential centrifugation, 
Percoll® density gradient centrifugation and washing in ISB without albumin. For heart 
mitochondria, the heart was finely chopped and incubated with bacterial protease prior to 
homogenisation as described elsewhere [24]. 
Oxygen electrode studies 
Rat liver (1 mg protein) or heart mitochondria (0.5 mg protein) were added to 2 mL 
respiration buffer (125 mM KCl, 20 mM MOPS, 10 mM Tris, 2.5 mM KPi, 0.5 mM EGTA, 
pH 7.2) in the chamber of an oxygen electrode (Hansatech Oxygraph) that was 
maintained at 30oC. The required substrates were then added (5 mM succinate plus 1 
µM rotenone; 5 mM L-glutamate plus 2 mM L-malate or 1 mM pyruvate plus 0.5 mM L-
malate) and rates of respiration determined before and after sequential additions of 0.5 
mM ADP, uncoupler (0.1 µM carbonyl cyanide p-trifluoromethoxyphenylhydrazone – 
FCCP) and the required concentration of LND or CHC. Further details are given in the 
Figure legends. 
Measurement of mitochondrial pyruvate transport 
This was performed in a cold-room (4oC) by measuring the uptake of [1-14C] pyruvate 
into liver mitochondria at 9oC using a modification of the dual label isotope technique 
described previously [20]. Uptake was terminated after 45 s (the linear phase of 
transport) by rapid sedimentation of mitochondria using a microcentrifuge. In outline, 
mitochondria were incubated on ice at 6 mg protein / mL in ISA containing the required 
concentration of LND. After 2 min, an aliquot (2 mL) was mixed with 3 mL of assay buffer 
(125 mM KCl, 20 mM MOPS, 0.5 mM EGTA, 1 µM rotenone at pH 6.8 and 20oC) 
containing [1-14C] pyruvate (0.1 mM and 5,000 Bq/mL) and 3H2O (25,000 Bq/mL) and 
then four 1 mL aliquots were immediately transferred to 1.5 mL microcentrifuge tubes. 
The tubes were transferred to an Eppendorff microcentrifuge (5415C) and, exactly 45 s 
after initial mixing, centrifuged at 10,000g for 1 min. The supernatants were rapidly 
removed and added to 0.1 mL 20% (w/v) perchloric acid (PCA) while the pellet was 
extracted in 0.5 mL water and 50 µL PCA (20% w/v) added. After removal of precipitated 
protein by centrifugation, samples of the pellet (0.5 mL) and supernatant (0.1 mL) were 
then assayed for [14C] and [3H] using a Packard TriCarb 2100 scintillation counter. A 
parallel experiment in which [U-14C] sucrose replaced the [1-14C] pyruvate was 
performed to enable the intra-mitochondrial [1-14C] pyruvate to be calculated from the 
total [1-14C] pyruvate in the pellet [20]. 
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Measurement of the rate of L-lactate uptake by Xenopus oocytes expressing different 
MCT isoforms 
This was carried out as described in detail elsewhere [25;26]. In outline, pGHJ plasmids 
containing the required MCT isoform were transcribed into cRNA which was then 
microinjected into Xenopus laevis oocytes. These were incubated for 3 days at 19oC to 
allow expression of the appropriate MCT at the plasma membrane of the oocyte. L-
Lactate transport into individual oocytes was then measured by incubating at room 
temperature (22oC) in assay buffer (75 mM NaCl, 2 mM KCl, 0.82 mM MgCl2, 1 mM 
CaCl2, 20 mM MES, pH 6.0) containing [U-14C] L-lactate (0.5 mM and 7.4 MBq / mL) and 
the required concentration of LND. Lactate uptake was confirmed to be linear with time 
for 5 min under these conditions [25;26]. Oocytes were then rapidly washed in ice-cold 
assay buffer prior to lysis in 0.5% (w/v) SDS and measurement of intracellular [U-14C]-L-
lactate by scintillation counting. 
Cell culture and LND treatment 
DB-1 human melanoma cells [27] were cultured in RPMI medium supplemented with 
10% fetal bovine serum, 100 units/mL penicillin, and 100 mg/liter streptomycin. LND 
was freshly prepared in DMSO. DB-1 cells were treated for 1 h with vehicle (0.1% (v/v) 
DMSO) or LND (1, 10, 40 or 150 µM) in RPMI medium without phenol red and fetal 
bovine serum. Three individual plates of cells were used per treatment condition. 
L-Lactate measurement 
Intracellular and extracellular L-lactate was measured as previously described [28] with 
modification. DB-1 cells were washed twice with phosphate-buffered saline (PBS) 
followed by scraping into 750 µL of ice-cold methanol/water (4:1, v/v) containing 2.5 µg 
of [13C3] lactate as internal standard. Samples were pulse-sonicated for 30 s. Medium 
collected from cell culture was centrifuged at 1,000 x g for 5 min to remove floating cells. 
Medium supernatant (200 µL) was mixed with 800 µL of ice-cold methanol and 75 ng of 
[13C4] succinate as internal standard. Both sonicated cell lysates and medium were then 
centrifuged at 16,000 × g for 10 min. The supernatants were transferred to clean tubes 
and evaporated to dryness under nitrogen. The dried residues were re-suspended in 100 
µL of water. L-lactate was analyzed using an Agilent 1200 series HPLC system coupled 
to an Agilent 6460 triple quadrupole mass spectrometer equipped with an electrospray 
ionization source operated in the negative ion mode. Analytes were separated by 
reversed-phase ion-pairing chromatography utilizing a Phenomenex Luna C18 column 
(150 × 2.00 mm, 3-µm particle size) at a flow rate of 200 µL/min maintained at 45°C. A 
two-solvent gradient system was used with solvent A as 200 mM 1,1,1,3,3,3-hexafluoro-
2-propanol and 5 mM ethyldiisopropylamine (DIPEA) in water and solvent B as 200 
mM 1,1,1,3,3,3-hexafluoro-2-propanol and 5 mM DIPEA in methanol. The linear gradient 
conditions were as follows: 2% B at 0 min, 2% B at 4 min, 95% B at 9 min, 95% B at 
12.5 min, 2% B at 13 min followed by a 4-min equilibration. 
Data fitting 
For the calculation of K0.5 values for LND inhibition of L-lactate and pyruvate transport, 
data were fitted by least squares regression analysis to the equation below using FigSys 
(Biosoft, Cambridge): 
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Rate as % control = 100 / (1+ ([I]/K0.5)^n) 
 [I] is the concentration of LND and n, the Hill coefficient which was set to 1 for 
mitochondrial pyruvate transport where no evidence of cooperativity was observed, and 
thus K0.5 represents the dissociation constant (Ki) of the inhibitor from the MPC. The 
K0.5 and n values determined from the fitted data are given ± the standard error (S.E.). 
For LND inhibition of respiration, data were fitted using the Bezier Spline function of 
FigSys except in the case of pyruvate oxidation by heart mitochondria. In this case data 
were fitted to an equation that assumes oxidation of pyruvate is set by the activity of 
PDH which in turn is controlled by the rate of pyruvate transport relative to that of PDH. 
The principle behind this approach and the mathematical analysis used is similar to that 
described previously [29]. In outline, the rate of pyruvate oxidation (V) is expressed in 
terms of the intramitochondrial [pyruvate] (Pin) assuming Michaelis Menten kinetics: 
v = Vpdh × [Pin]/(Pin + Kpdh) Equation 1 
where Vpdh is the Vmax of PDH expressed as % of the rate of pyruvate oxidation in the 
absence of LND, and Kpdh is the Km of PDH (set at 40 µM [30]). This rate of pyruvate 
oxidation must also be the same as the net rate of pyruvate transport expressed as the 
influx rate minus the efflux rate. This is given by: 
v = (Vmpc × [Pout]/(Pout + Kmpc) - Vmpc × [Pin]/(Pin + Kmpc)) × A   Equation 2 
where Vmpc is the Vmax of the MPC expressed as % of the rate of pyruvate oxidation in 
the absence of LND, Kmpc is the Km of MPC (set at 150 µM [20]), [Pout] the 
extramitochondrial [pyruvate], and A the activity of the MPC in the presence of LND 
expressed as a fraction of the activity in the absence of LND. The value of A is itself 
calculated assuming that LND inhibits competitively with pyruvate on the inner face of 
the MPC as is the case for CHC [31] and that the concentration of LND in the matrix is 
the same as in the medium. Thus: 
A = (Pin + Kmpc )/(Pin + Kmpc  × (1+I/Ki))   Equation 3 
where I is the concentration of LND and Ki its dissociation constant. Combining 
equations 1 and 2 generates a quadratic equation from which [Pin] can be calculated 
using regression analysis and hence the rate of pyruvate oxidation using Equation 1. It 
should be noted that for simplicity our analysis has ignored any small MPC-independent 
rate of pyruvate transport into mitochondria. We have reanalyzed the data including such 
a parameter but the calculated value for the inhibitor independent rate was not 
significantly different from zero. For all analyses using regression analysis, the 
parameter values are derived with standard errors (S.E.) and thus a 95% confidence 
interval (2 × S.E). Values were only considered significantly different when there was no 
overlap in this value.  
 
 
RESULTS 
LND inhibits mitochondrial pyruvate transport with a Ki of 2.5 µM 
We used isolated rat liver mitochondria to investigate whether LND inhibits the 
mitochondrial pyruvate carrier (MPC). Uptake of [1-14C] pyruvate (60 µM) was measured 
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at 45 s in the presence of rotenone and 9oC to prevent significant pyruvate metabolism. 
To ensure accumulation of pyruvate, uptake was energised using an artificially induced 
pH gradient (pH 6.8 outside, pH 7.4 inside) as described under Methods. We have 
previously validated this method as suitable to provide true initial rates of pyruvate 
transport [20].  As shown in Fig. 1A, increasing concentrations of LND produced a 
progressive inhibition of pyruvate uptake with a Ki value (± S.E. of the fit shown) of 2.5 ± 
0.1 µM.  Fig. 1A also includes data for inhibition of the mitochondrial pyruvate carrier by 
the well-characterised MPC inhibitor, CHC, which produced >90% inhibition at 10 µM. 
We confirmed the inhibition of mitochondrial pyruvate transport in rat heart mitochondria 
by measuring the effects of LND on the rate of uncoupled pyruvate-dependent 
respiration at 30oC as shown in Fig. 1B. The lowest concentration of LND used (2 µM) 
was without effect on pyruvate oxidation since the MPC does not limit respiration under 
these conditions [32]. However, after addition of 3 µM LND, significant (~15%) inhibition 
was observed and approached 70% by 10 µM, close to the inhibition of pyruvate 
transport in liver mitochondria by 10 µM CHC. As described in Methods, we were able to 
fit the data to an equation that assumes oxidation of pyruvate is set by the activity of 
PDH which in turn is controlled by the rate of pyruvate transport relative to that of PDH. 
The fit shown in Fig. 1B assumes published Km values for the MPC (150 µM) and PDH 
(40 µM) and the Ki for LND of 2.5 µM derived from the data of Fig. 1A. The calculated 
Vmax values for PDH and the MPC (± S.E. and expressed as a percentage of the 
maximum rate of oxygen consumption in the absence of LND) were 127 ± 6.3 and 233 ± 
9.1, respectively. This analysis confirms that the IC50 for LND inhibition of uncoupled 
pyruvate oxidation (~ 7.5 µM) is entirely consistent with its inhibition of the MPC whose 
activity is significantly greater than that of PDH. 
LND cooperatively inhibits MCT1, MCT2 and MCT4 less potently than MPC 
The effects of LND on L-lactate transport by MCT1, MCT2 and MCT4 were investigated 
using Xenopus laevis oocytes expressing each of the isoforms individually. This was 
achieved by microinjection of the relevant cRNA and culture for 72 hr as described 
previously [25]. In the case of MCT2, co-injection of the cRNA for embigin, the preferred 
ancillary protein of MCT2 [33], was required to give high expression levels of the 
transporter, whereas for MCT1 and MCT4 maximal levels of expression were supported 
by endogenous basigin [25;26]. Expression of each of the MCT isoforms gave a similar 
enhancement of 0.5 mM [U-14C] L-lactate transport compared to water-injected oocytes 
as shown in Fig.2A. Increasing concentrations of LND produced a progressive inhibition 
of L-lactate uptake for all isoforms as shown in Panels B-D of Fig. 2. Data are expressed 
as percentage of rates in the absence of inhibitor to allow easier comparison between 
experiments on different days and with different isoforms. For each isoform, data could 
be fitted using the equation for cooperative non-competitive inhibition as described under 
Methods. Derived K0.5 values (± S.E. of the fit shown) for MCT1, MCT2 and MCT4 are 
36.8 ± 3.1, 36.4 ± 3.6 and 40.4 ± 2.2 µM, respectively, with corresponding values for the 
Hill coefficient of 1.65 ± 0.23, 1.86 ± 0.34 and 1.84 ± 0.19. 
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LND inhibits uncoupled mitochondrial pyruvate oxidation more potently than 
glutamate + malate or succinate oxidation. 
Previous reports have suggested that LND affects mitochondrial respiration with different 
sensitivities depending on the substrate employed (Floridi & Lehninger, 1983). Figure 3A 
shows that the effect of LND on uncoupled pyruvate oxidation by rat heart mitochondria 
was significantly greater than that on the oxidation of other respiratory substrates, which 
is entirely consistent with a dominant effect of the inhibitor on the MPC as opposed to 
the respiratory chain. Liver mitochondria, unlike heart mitochondria, do not oxidize 
pyruvate rapidly, and the MPC does not exert much control over its oxidation [34]. 
However, uncoupled respiration in the presence of either glutamate + malate or 
succinate (in the presence of rotenone) is rapid and the data of Fig. 3B confirm that LND 
inhibits both with IC50 values of 25 and 150 µM, respectively. The data with succinate 
closely match similar data obtained in uncoupled mouse liver mitochondria where we 
also demonstrated that LND inhibits succinate-ubiquinone reductase activity of 
respiratory complex II with an IC50 of about 300 µM [28]. This is substantially higher than 
the Ki for the MPC and IC50 for pyruvate and glutamate + malate oxidation. It should be 
noted that for both liver and heart mitochondria the inhibition of glutamate + malate 
oxidation by LND appears to be biphasic. We have not investigated this further, but it 
could reflect two pathways of glutamate oxidation known to operate in isolated 
mitochondria. Oxidation via glutamate dehydrogenase can occur, especially in liver 
mitochondria. However, the more prominent pathway is via transamination with 
oxaloacetate, formed by malate oxidation, to yield aspartate, which leaves the 
mitochondria in exchange for the incoming glutamate on the glutamate / aspartate 
carrier [35;36]. 
Effects of LND on L-lactate output by DB-1 melanoma cells 
It would be predicted that inhibition of the MPC by low concentrations of LND (MPC 
specific) would cause a decrease in pyruvate oxidation and thus an increase in L-lactate 
output as glycolysis compensates for the resulting decrease in mitochondrial ATP 
production. Conversely, higher LND concentrations, which also inhibit the MCTs, should 
decrease L-lactic acid efflux with a corresponding rise in intracellular [L-lactate]. We 
performed experiments with isolated DB-1 melanoma cells that confirmed this prediction 
as shown in Fig. 4. We found that 1-10 µM LND increased L-lactate output (Panel A), 
consistent with MPC inhibition, and this occurred without a detectable increase in 
intracellular [L-lactate] (Panel B). However, higher LND concentrations, 40 µM and 150 
µM, caused intracellular [L-lactate] to increase by two-fold and eight-fold, respectively, 
(Panel B) with a corresponding decrease in L-lactate output, consistent with MCT 
inhibition (Panel A). 
 
  
DISCUSSION  
Mitochondrial sites of action of lonidamine on tumour cell energy metabolism 
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In 1981, Floridi et al. reported that in Ehrlich ascites and various other tumour cells LND 
inhibited respiration as well as aerobic and anaerobic glycolysis, but had no effect on 
normal rat Sertoli cells [14;37;38]. They attributed the selective inhibition of glycolysis in 
tumour cells by LND to its inhibition of mitochondria-bound hexokinase 2 that Pedersen 
et al. [39] had shown was strongly expressed in many tumour cells. However, 
subsequent studies demonstrated that LND directly inhibited the uncoupled respiration 
of mitochondria from Ehrlich ascites fueled by various NAD- and FAD-linked substrates 
but not duroquinol, that feeds electrons directly into complex 3, or ascorbate + N,N,N’,N’- 
tetramethyl-p-phenylenediamine (TMPD) that feeds electrons into complex 4 via 
cytochrome c [22;40]. The authors concluded that LND inhibits succinate oxidation within 
complex 2 of the respiratory chain, which our subsequent studies confirmed [28], while 
oxidation of pyruvate + malate and other NAD-linked substrates involved a decrease in 
mitochondrial NADH generation, which might indicate inhibition of dehydrogenases 
activity. The data we present in Fig. 1B and Fig. 3 are entirely consistent with this 
proposal but suggest that the more potent effect on pyruvate oxidation actually reflects 
the inhibition of the MPC by LND. 
Lonidamine is a potent inhibitor of the mitochondrial pyruvate carrier 
In Fig. 1A, we demonstrate directly that LND inhibits the MPC with a Ki of 2.5 ± 0.1 µM, 
which is similar to the Ki value determined previously for the well-established MPC-
inhibitor CHC [20]. Fig. 1B confirms that this inhibition can account for the inhibition 
profile of uncoupled oxidation of pyruvate by isolated heart mitochondria. These data 
were fitted to an equation that assumes oxidation of pyruvate is set by the activity PDH 
which in turn is controlled by the rate of pyruvate transport relative to that of PDH. Using 
the derived Ki value for LND of 2.5 µM, the data generated Vmax values for PDH and the 
MPC (± S.E. and expressed as a percentage of the maximum rate of oxygen 
consumption in the absence of LND) of 127 ± 6.3 and 233 ± 9.1, respectively. Since the 
rate of oxygen consumption in the absence of LND is known (87.9 ± 5.8 nmol O2 . min-1 
per mg protein), the Vmax values for PDH and the MPC can be calculated as 112 and 205 
nmol O2 . min-1 per mg protein, respectively. If it is assumed that pyruvate is oxidized 
totally to CO2 and water, then 2.5 nmol O2 are used to oxidize 1 nmol of pyruvate, and 
this allows calculation of true Vmax values for PDH and the MPC at 30oC of 45 and 82 
nmol.min-1 per mg protein. By measuring the temperature-dependence of the proton 
fluxes associated with mitochondrial pyruvate uptake, the activation energy of the MPC 
in rat liver mitochondria was determined to be 113 kJ.mol-1 [20]. Using this value, 
together with the Km of the MPC (150 µM [20]) and the rate of transport measured 
directly at 9oC and 60 µM pyruvate in Fig. 1A (0.303 nmol per mg protein in 45s), the 
Vmax of the MPC in liver mitochondria at 30oC can be calculated to be 34.7 nmol.min-1 
per mg protein. The concentrations of the MPC in rat heart and liver mitochondria were 
determined by inhibitor binding studies to be 56 and 26 pmol per mg protein, 
respectively [32], and this would give a value for the Vmax of the MPC in heart 
mitochondria of 74.8 nmol.min-1 per mg protein, which is in reasonable agreement with 
the value of 82 nmol.min-1 per mg protein derived from the data of Fig. 1B. 
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Lonidamine also inhibits MCT1, MCT2 and MCT4, but less potently than the MPC. 
There are four members of the proton-linked monocarboxylate transporter (MCT) family 
that are known to transport L-lactate of which the dominant isoforms expressed in 
tumour cells are MCT1 and MCT4 with some tumours also expressing MCT2 [18;41]. 
The data of Fig. 1 show that each of these isoforms is inhibited cooperatively by LND 
with similar values for K0.5 and Hill coefficients of 36-40 µM and 1.65-1.85, respectively. 
The K0.5 value is more than an order of magnitude higher than its Ki for inhibition of the 
MPC, a characteristic also displayed by CHC [18]. However, the ability of LND to inhibit 
L-lactate transport by all three MCT isoforms with a similar potency is quite different from 
other well-established MCT inhibitors such as CHC and 6-[(3,5-Dimethyl-1H-pyrazol-4-
yl)methyl]-5-[[(4S)-4-hydroxy-2-isoxazolidinyl]carbonyl]-3-methyl-1-(2-
methylpropyl)thieno[2,3-d]pyrimidine-2,4(1H,3H)-dione (AR-C155858). These inhibitors 
bind to the substrate binding site of the transporter and like substrates show a much 
higher affinity for MCT1 and MCT2 than MCT4 [25;42;43]. It may also be significant that 
inhibition by LND, unlike CHC and AR-C155858, is cooperative with a Hill coefficient that 
is close to 2. MCTs operate as dimers in association with two copies of the ancillary 
protein embigin or basigin [44], and thus it is possible that LND binds at an interface of 
the two MCT monomers that are shared by all isoforms. 
 
Integrating the known actions of lonidamine into a mechanism for its anti-tumour 
effects 
Carbon-13 NMR studies of perfused DB-1 melanoma cells indicate that these tumours 
obtain about 46% of their ATP from glycolysis and 54% from oxidative phosphorylation 
[45]. Under in vivo conditions, substantial levels of hypoxia would be anticipated, 
increasing the glycolytic contribution; but given its much higher ATP-production 
efficiency, oxidative metabolism would still account for a large fraction of tumour energy 
production. Our data indicate that the most avid target site for LND is the MPC (Ki, 2.5 
µM) while half maximal inhibition of the MCT1 and MCT4 (the two MCT isoforms 
expressed in DB-1 cells [46]) only occurs at 36-40 µM, more than an order of magnitude 
greater. The inhibition of the MPC by LND accounts for its ability to inhibit pyruvate 
oxidation with an IC50 of ~7.5 µM which is substantially lower than its IC50 for inhibition of 
other respiratory substrates (25 µM for glutamate plus malate and 150 µM for succinate). 
Thus, it would be predicted that the lowest concentrations of LND will only inhibit 
pyruvate oxidation leading to increase rates of glycolysis and L-lactic acid production. 
The data of Fig. 4A confirm this prediction in DB-1 melanoma cells. At higher LND 
concentrations, oxidation of glutamine (via glutamate) would also be inhibited which has 
the potential to enhance glycolysis further. However we do not observe a further 
increase in L-lactate output, probably because these higher LND concentrations will also 
begin to inhibit L-lactic acid efflux on MCT1 and MCT4. The data of Fig. 4B confirm this 
since intracellular [L-lactate] increases by two-fold and eight-fold at 40 µM and 150 µM 
LND, respectively. MCT1 and MCT4 are expressed about equally in DB-1 melanoma 
cells [46], and although both are inhibited with a similar K0.5, the effect on MCT4 is likely 
to be less significant initially since MCT1 has a much lower Km (5 mM) than MCT4 (25 
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mM) [18] and thus will be responsible for the majority of L-lactic acid efflux at the lower 
intracellular [L-lactate]. 
As inhibition of MCT1 and MCT4 increases at higher [LND], the accumulation of 
intracellular L-lactate would be predicted to cause a drop in pHi. Our previous studies 
using DB-1 xenografts in mice that were injected with LND (100 mg/kg, i.p.) detected 
such changes [5]. Thus, using P-31 NMR to measure pHi and energy status, and H-1 
NMR to measure intracellular [L-lactate], we demonstrated a selective decrease in 
tumour pHi from 6.9 ± 0.1 to 6.3 ± 0.1 within about 40 min of LND treatment.  This was 
associated with a three-fold rise in [L-lactate]. No significant change in pHi of normal 
muscle or brain was detected, and only a slight transient change in pHi of liver was 
observed at 20 min post-injection [5]. A slight decrease in extracellular pH of the tumour 
(~0.2 pH units) was also observed and could be explained by some of the increased L-
lactic acid produced leaving the cell via residual MCT activity and via free diffusion which 
is enhanced at low pH [18]. Concomitant with these changes, there was a slow 
monotonic decrease in the bioenergetic status of the tumour consisting of a decrease in 
nucleoside triphosphates (including ATP) and an increase in inorganic phosphate (Pi). 
The overall effect was a 66.8 ± 5.7% decrease in the NTP/Pi ratio within about 3 hr [5]. 
Again this bioenergetic decline is tumour specific, with no change in the NTP/Pi ratio of 
muscle and brain and only a transient small decrease in NTP/Pi of the liver at 40 min 
post-injection of the drug. 
It would seem likely that the ability of LND to inhibit the MPC is critical because it 
may enhance the consequences of inhibiting MCT activity by preventing oxidation of the 
accumulated L-lactate through its conversion to pyruvate, entry into the mitochondria 
and oxidation via PDH and the citric acid cycle. This prevents the cell from 
compensating for the loss in glycolytic ATP by up-regulating oxidative phosphorylation, 
an effect further curtailed by inhibition of the respiratory chain. Recently, the effects on 
cancer cell growth and metabolism on knocking down Mpc1 and Mpc2, two proteins 
recently identified as components of the MPC [47;48], have been investigated [49;50]. 
Mpc1 was shown to be down-regulated or absent in many tumours and its over-
expression impaired tumour cell growth [49], which does not fit easily with our data 
implicating inhibition of the MPC in the anti-tumour effects of LND. However, although it 
is now widely accepted that Mpc1 and Mpc2 form a multimeric MPC complex [51], 
questions have been raised over whether these proteins might exert their effects on 
pyruvate metabolism rather than transport [52]. In this context, it may be significant that 
measurement of the isotope flux of [13C] into citrate from [U-13C]-glucose and [U-13C]-
glutamine shows the specific MPC inhibitor UK5099 to have a much more profound 
effect on the labelling pattern of citrate than does Mpc1 or Mpc2 knockdown [50].  
 
Conclusions 
Our data suggest that the combined inhibition of the MPC and MCTs by LND prevents 
both efflux of glycolytically derived L-lactic acid from the cell and its oxidation by 
mitochondria. The resulting decrease in intracellular pH inhibits glycolysis and with the 
cell unable to compensate by oxidizing L-lactate / pyruvate, the cell experiences a 
bioenergetic crisis which is aggravated by the effects of LND on the oxidation of other 
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substrates such as glutamine. This proposal is supported by published data on the 
selective tumour effects of LND on L-lactate, pHi and ATP levels [5] and by similar 
effects described for the established MPC and MCT inhibitor α-cyano-4-
hydroxycinnamate [19]. Delineation of why LND appears to be tumour-specific when all 
cells are dependent on the activity of either or both the MPC and MCTs remains to be 
determined. However, it could simply reflect the expression levels of MCT isoforms and 
the MPC relative to rates of metabolism dependent on them. 
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Figure 1  Lonidamine inhibits pyruvate transport into mitochondria 
In Panel A pyruvate transport into liver mitochondria was assayed directly at 9oC using 
[1-14C]-pyruvate as described under Methods. Data are presented as Means ± S.E.M. for 
3 separate mitochondrial preparations. In each experiment, four replicates were 
performed at each LND concentration and the average value taken to calculate the 
extent of inhibition as percentage of control (no LND). Data were fitted to the standard 
inhibition equation (see Methods) to give a derived Ki value of 2.5 ± 0.1 µM. The 
absolute rate of pyruvate (60 µM) uptake in the absence of LND was 0.303 ± 0.032 nmol 
per mg protein in 45s. Panel B shows data for the inhibition of uncoupled pyruvate 
oxidation by isolated rat heart mitochondria at 30oC measured using an oxygen 
electrode as described under Methods. Mean data (± S.E.M.) are presented for 3 
separate mitochondrial preparations. The absolute rate of pyruvate oxidation in the 
absence of LND was 87.9 ± 5.8 nmol O2 . min-1 per mg protein. The data were fitted to 
an equation that assumes oxidation of pyruvate is set by the activity PDH which in turn is 
controlled by the rate of pyruvate transport relative to that of PDH as described under 
Methods. The Ki value for LND of 2.5 µM derived from Panel A was employed and the 
Vmax of PDH and MPC activity (expressed as % control rate of oxygen consumption and 
± S.E.) were then calculated by least squares regression analysis to be 127 ± 6.3 and 
233 ± 9.1, respectively 
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Figure 2  Lonidamine inhibits the proton-linked monocarboxylate carriers MCT1, 
MCT2 and MCT4 
[U-14C]-L-lactate uptake into Xenopus laevis oocytes expressing the MCT isoform 
indicated was determined as described in Methods. Panel A shows the absolute rates of 
L-lactate uptake while Panels B-D show the effects of increasing concentrations of LND 
on rates of L-lactate uptake into oocytes expressing MCT1, MCT2 or MCT4 as indicated. 
Rates are expressed as a percentage of the control (no LND) after subtraction of the 
uptake by water-injected oocytes. Each data point represents mean data ± S.E.M. for 
10-45 individual oocytes and data were fitted to the equation for cooperative inhibition 
using FigSys as described in Methods. The derived values for K0.5 and the Hill 
Coefficient (n) are indicated on each plot (± S.E. of the fit shown). 
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Figure 3  Lonidamine inhibits oxidation of glutamate, 2-oxoglutarate and succinate 
by uncoupled rat heart and liver mitochondria less potnetly than pyruvate transport 
Rates of oxidation by isolated rat heart (A) or liver (B) mitochondria at 30oC were 
measured using an oxygen electrode as described under Methods. Data are expressed 
as the percentage of rates in the absence of LND to allow better comparison between 
the different substrates and the lines drawn were fitted by FigSys using a Bezier Spline 
function. For heart mitochondria, data are presented for a single representative 
experiment with absolute rates of pyruvate + malate, glutamate + malate, 2-oxoglutarate 
+ malate and succinate + rotenone oxidation in the absence of LND of 84, 83, 67 and 
212 nmol O2 . min-1 per mg protein , respectively. For liver mitochondria (B), mean data 
(± S.E.M.) are presented for 3 separate mitochondrial preparations. The absolute rates 
of glutamate + malate and succinate (+ rotenone) oxidation in the absence of LND were 
67.9 ± 3.0 and 109 ± 7.8 nmol O2 . min-1 per mg protein, respectively. 
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Figure 4  Concentration dependence of lonidamine effects on DB-1 melanoma cell 
L-lactate output and intracellular [L-lactate]. 
DB-1 cells were incubated with DMSO or LND at the indicated concentrations for 1 h. 
Levels of [L-lactate] in the culture medium (A) and intracellular [L-lactate] (B) were 
determined by LC-MS as described under Methods. The levels of [L-lactate] in the LND-
treated group were normalized to the levels in DMSO controls. Data are presented as 
Means ± S.D. for 3 samples. 
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